Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
2005 2
2007 2
2008 3
2009 3
2010 1
2011 1
2013 1
2014 2
2015 1
2016 2
2018 2
2019 3
2020 5
2021 5
2022 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Eisenmenger syndrome: diagnosis, prognosis and clinical management.
Arvanitaki A, Giannakoulas G, Baumgartner H, Lammers AE. Arvanitaki A, et al. Heart. 2020 Nov;106(21):1638-1645. doi: 10.1136/heartjnl-2020-316665. Epub 2020 Jul 20. Heart. 2020. PMID: 32690623 Review.
Eisenmenger syndrome (ES) represents the most severe phenotype of pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) and occurs in patients with large unrepaired shunts. ...Close follow-up is needed to early diagnose and timely mana …
Eisenmenger syndrome (ES) represents the most severe phenotype of pulmonary arterial hypertension (PAH) associated with congen …
Macitentan in the treatment of pulmonary arterial hypertension.
Zebadúa R, Hernández-Pérez AP, García A, Zayas N, Sandoval J, López J, Pulido T. Zebadúa R, et al. Future Cardiol. 2021 Jan;17(1):49-58. doi: 10.2217/fca-2020-0012. Epub 2020 Jul 17. Future Cardiol. 2021. PMID: 32677463 Review.
Endothelin receptor antagonists are a class of drugs that have been approved as PAH therapy. Macitentan is a lipophilic, tissue specific, dual receptor antagonist with a higher potency than bosentan and a reduced risk of hepatic injury. ...
Endothelin receptor antagonists are a class of drugs that have been approved as PAH therapy. Macitentan is a lipophilic, tissue speci …
Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease.
Arshad HB, Duarte VE. Arshad HB, et al. Methodist Debakey Cardiovasc J. 2021 Jul 1;17(2):145-151. doi: 10.14797/UFEJ2329. eCollection 2021. Methodist Debakey Cardiovasc J. 2021. PMID: 34326934 Free PMC article. Review.
Pulmonary arterial hypertension (PAH) has a multifactorial etiology depending on the size and nature of the cardiac defect as well as environmental factors. Although progress has been made in disease-targeting therapy using pulmonary vasodilators to treat Eisenmenger …
Pulmonary arterial hypertension (PAH) has a multifactorial etiology depending on the size and nature of the cardiac defect as well as enviro …
A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M. Bedan M, et al. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113. doi: 10.1111/bcpt.13033. Epub 2018 Jun 5. Basic Clin Pharmacol Toxicol. 2018. PMID: 29719121 Free article. Review.
In the EARLY study (NCT00091715), bosentan showed improvements in 6MWD which were not statistically significant. Bosentan had an effect on PAH in patients with Eisenmenger syndrome (ES) in the BREATHE-5 study (NCT00367770), while macitentan did not improve 6MWD in t …
In the EARLY study (NCT00091715), bosentan showed improvements in 6MWD which were not statistically significant. Bosentan had an effect on P …
Eisenmenger Syndrome in Pregnancy: A Management Conundrum.
Lopez BM, Malhamé I, Davies LK, Gonzalez Velez JM, Marelli A, Rabai F. Lopez BM, et al. J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2813-2822. doi: 10.1053/j.jvca.2020.02.053. Epub 2020 Mar 6. J Cardiothorac Vasc Anesth. 2020. PMID: 32381307 No abstract available.
Review of evidence for bosentan therapy for treatment of Eisenmenger syndrome.
Hartwig BJ, Schultze B. Hartwig BJ, et al. J Am Assoc Nurse Pract. 2019 Jan;31(1):72-77. doi: 10.1097/JXX.0000000000000104. J Am Assoc Nurse Pract. 2019. PMID: 30475252 Review.
BACKGROUND AND PURPOSE: Eisenmenger syndrome (ES) is a rare condition caused by a right-to-left cyanotic shunt. ...Those articles considered relevant based on the abstract were read in entirety. CONCLUSIONS: Eisenmenger syndrome remains incurable excep …
BACKGROUND AND PURPOSE: Eisenmenger syndrome (ES) is a rare condition caused by a right-to-left cyanotic shunt. ...Those artic …
Eisenmenger Syndrome in Adults: Treatment Pattern and Prognostic Factors in the Advanced Pulmonary Vasodilator Era.
An HS, Kim GB, Song MK, Bang JS, Lee SY, Bae EJ, Noh CI. An HS, et al. Pediatr Cardiol. 2019 Jan;40(1):23-28. doi: 10.1007/s00246-018-1956-y. Epub 2018 Aug 18. Pediatr Cardiol. 2019. PMID: 30121863
Patients with Eisenmenger syndrome (ES) have a higher mortality rate than patients with simple congenital heart disease (CHD). ...Low SpO(2) and platelet count were related to mortality in adult ES, especially in those with simple CHD. Therefore, careful attention s …
Patients with Eisenmenger syndrome (ES) have a higher mortality rate than patients with simple congenital heart disease (CHD). …
Risk Assessment Tool Implementation in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
Yaylalı YT, Yağmur B, Sinan ÜY, Meriç M, Başarıcı İ, Kılıçkıran Avcı B, Şenol H, Nalbantgil S, Küçükoğlu S, Öngen Z. Yaylalı YT, et al. Anatol J Cardiol. 2023 Aug 1;27(8):479-485. doi: 10.14744/AnatolJCardiol.2023.2885. Epub 2023 Jun 7. Anatol J Cardiol. 2023. PMID: 37288853 Free PMC article.
Thirty-two patients died during follow-up period. Most patients were Eisenmenger syndrome (31%) and simple defects (29.4%). Most patients received monotherapy (76.2%). ...Patients not achieving low risk at follow-up may benefit from aggressive use of available th …
Thirty-two patients died during follow-up period. Most patients were Eisenmenger syndrome (31%) and simple defects (29.4%). Mo …
Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies.
D'Alto M, Diller GP. D'Alto M, et al. Heart. 2014 Sep;100(17):1322-8. doi: 10.1136/heartjnl-2014-305574. Epub 2014 May 14. Heart. 2014. PMID: 24829371 Review.
Pregnancy conveys significant risks in PAH-CHD patients: appropriate counselling and care, including psychological support and a multidisciplinary team, should be part of the routine management of women with PAH-CHD of reproductive age. Some subgroups, such as patients wit …
Pregnancy conveys significant risks in PAH-CHD patients: appropriate counselling and care, including psychological support and a mult …
Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management.
Papamichalis M, Xanthopoulos A, Papamichalis P, Skoularigis J, Triposkiadis F. Papamichalis M, et al. Heart Fail Rev. 2020 Sep;25(5):773-794. doi: 10.1007/s10741-019-09847-5. Heart Fail Rev. 2020. PMID: 31407139 Review.
Depending on the location and magnitude of the defect as well as the time of surgical correction, the patient with ACHD is at risk of developing pulmonary arterial hypertension (PAH), which dramatically increases morbidity and mortality. It is encouraging that therapies ap …
Depending on the location and magnitude of the defect as well as the time of surgical correction, the patient with ACHD is at risk of develo …
33 results